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FGF-23Abstract Background: Tumour-induced osteomalacia (TIO) is a rare clinical entity in which sec-
ondary osteomalacia is induced by tumour-related products. There is impaired reabsorption of
phosphorus in the renal tubules and hypophosphatemia as a result of over expression of FGF-23
mRNA. Treatment of choice is considered to be total or near total resection of the tumour.
Methods and results: A 49-year-old man had experienced systemic bone pain and bilateral limb
weakness for several months. He had refractory hypophosphatemia and marked elevation of serum
FGF-23 level. Magnetic resonance imaging (MRI) of the lumbar spine showed a focal lesion in the
left temporal bone which was hyper metabolic on positron emission tomography (PET) scan, lead-
ing to a diagnosis of TIO. He underwent lateral skull-base surgery after thorough evaluation of the
tumour. After the en bloc resection, FGF-23 became gradually undetectable, phosphate reabsorp-
tion normalised, and all symptoms were resolved.
Conclusions: We present the clinical features and treatment options for this most unusual man-
ifestation of phosphaturic mesenchymal tumour in the temporal bone.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Ear, Nose, Throat and
Allied Sciences.1. Introduction
Impaired mineralization of osteoid matrix in mature bone
leads to a metabolic disorder known as Osteomalacia.
Fanconi’s syndrome and FGF-23 secreting mesenchymal
tumours are acquired causes of Osteomalacia; the latter
referred to as TIO or oncogenic osteomalacia.1
Last member of FGF family was identiﬁed as the
Fibroblast growth factor 23 (FGF23). It is produced by
bone and reduces serum phosphate level by suppressing
phosphate reabsorption in proximal tubules and intestinal
150 G. Ashish et al.phosphate absorption through lowering 1,25-dihydroxy
vitamin D level. It has been shown that excess levels of
FGF23 result in hypophosphatemic rickets/osteomalacia.2
A rare para neoplastic form of renal phosphate wasting
which results in phosphaturia, due to defect in vitamin D
metabolism, and osteomalacia is known as TIO (Tumour-
induced osteomalacia).3,1,4
Tumour induced osteomalacia (TIO) is a rare and often
unrecognised cause of hypophosphatemia in subjects with
adult onset osteomalacia.
We report a case of a 49-year-old man with TIO caused by
a FGF-23 secreting mesenchymal tumour localised in the left
temporal bone. Conﬁrmation of the diagnosis was obtained
by biopsy which revealed a phosphaturic mesenchymal tumour
secreting FGF 23. The patient subsequently underwent surgery
with en bloc removal of the tumour and subsequent normalisa-
tion of biochemical abnormalities.
To our knowledge, this paper represents the ﬁrst docu-
mented case of a phosphaturic mesenchymal tumour secreting
FGF 23 located in the temporal bone from India. Our case
also highlights the importance of considering TIO when assess-
ing patients with low serum phosphate.
2. Case report
A 49 year old gentleman, presented with the history of pain in
bilateral lower limb for 3 years and difﬁculty in walking for
1 year. Initially it started with pain in right knee, which grad-
ually progressed with involvement of left knee and bilateral hip
and whole of lower limb. Initially he had difﬁculty in getting
up from ﬂoor and climbing stairs which progressed to need
support to get up and use walker for ambulation. He also
complained of decreased hearing and intermittent low intensity
tinnitus in left ear for the last 1 year.
Ear examination suggested a ﬂeshy mass occluding the left
external ear. Bilateral facial nerve was intact on clinical
examination. A MR-CT (Fig. 4) revealed a fairly well deﬁned
heterogeneous mass in the left temporal bone, showing iso-Figure 1 T1W1: Line pointing towards lesion in the left
temporal bone.intensity on T1-weighted images (T1WI) (Figs. 1 and 2),
high-intensity on T2WI (Fig. 3), and enhancement with gado-
linium in left jugular foramen extending into middle ear cavity
and external ear .The lesion caused erosion of middle ear ossi-
cles, bony labyrinth, and facial nerve canal along with moth
eaten pattern of bony destruction in the adjacent skull base.
On evaluation patient was found to have hypophosphate-
mia (1.7 mg %) with Tmp GFR< 0.9, normal serum calcium
level (Ca: 9.4 mg/dL) and low serum 1, 25(OH) 2D.
Pure tone audiogram suggested moderate degree of conduc-
tive hearing loss in the left ear.
A biopsy of the ﬂeshy mass was done which conﬁrmed a
FGF 23 secreting mesenchymal tumour. He was posted for
enbloc excision of the tumour via a lateral skull base approach.
Per op ﬁndings suggested that tumour was ﬁlling the mas-
toid antrum, aditus, epitympanum, and mesotympanum and
hypo tympanum. Sinus plate and dural plate thinned out. Lat-
eral semicircular canal and tympanic segment of the facial
nerve eroded. Ossicles were intact but encased in the tumour.
Malleus and incus had to be removed along with the tumour
tissue in the middle ear. Anterior part of the superior semicir-
cular canal eroded. Facial bridge removed and ridge lowered.
Middle ear and mastoid obliterated with fat and lined with fas-
cia lata and temporalis fascia. En bloc excision of the tumour
was done with Cul-de-sac closure of the external auditory
canal.
Histopathological examination was consistent with FGF 23
secreting mesenchymal tumour.
Immuno histochemistry suggested that the tumour cells
were immunopositive for vimentin but negative for SMA,
S-100 and CD34 (Figs. 5–7).
He had a high FGF 23 pre operatively and his phosphate
levels stabilised after surgery. He had been on Neutral phos-
phate for 6 weeks. By post-operative week 4, the FGF-23 level
was undetectable (preoperative value was 449 RU/mL, and the
value on postoperative 6th week was 37 RU/mL) Thereafter,
phosphate reabsorption (Tmp/GFR) normalised and all his
symptoms improved gradually. Post operative review Comput-
erised tomography shows soft tissue density in the external
auditory canal signifying fat and soft tissue as a result of
cul-de-sac closure with complete resolution of the pathologyFigure 2 T1W1 coronal view.
Figure 3 T2W1: Line pointing towards the lesion.
Figure 4 CT Scan image.
Figure 5 Vimentin positive.
Figure 6 SMA negative.
Figure 7 S 100 negative.
Figure 8 Post op CT scan: line pointing to cul-de-sac closure
with fat and soft tissue and another line suggesting resolution of
tumour in the left temporal bone area.
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in our outpatient clinic without recurrence for 8 months.3. Discussion
TIO was ﬁrst recognised as a disease by Prader et al in 1959.5
Tumour induced osteomalacia (TIO) is a rare para neoplas-
tic syndrome characterised by hypophosphatemia and abnor-
mal vitamin D metabolism. Usually small tumours that
secrete the phosphaturic hormone ﬁbroblast growth factor 23
(FGF23) cause this entity.6
Clinicians are often unaware of the existence of TIO, and
even if TIO is recognised as a possible diagnosis, localising
the instigating tumour may be very difﬁcult .Most patients
with TIO can have symptoms for up to 10 years before a deﬁn-
itive diagnosis is made.7 This was indeed the case for the pres-
ent patient, for whom it took 3 years to ﬁnd a primary lesion.
Symptoms of hypophosphatemia include fatigue, weakness,
bone pain and occasionally fractures. About 2/3 of dietary
phosphate is absorbed in the proximal part of the intestine
(duodenum and ileum). The circulating phosphate is ﬁltered
by the glomerulus and 85–95% of ﬁltered phosphate is reab-
sorbed in the proximal tubule of the kidney. Renal phosphate
reabsorption can only increase up to a threshold and thereafter
phosphate is excreted in the urine.8
FGF23 regulates the phosphate homeostasis via 2 mecha-
nisms. First, FGF23 binds to FGF receptor 1c and its co
receptor known as klotho, and activation of this receptor com-
plex inhibits reabsorption of phosphate by down expression of
sodium-phosphate transporters in the proximal tubule.
Secondly, it also decreases the synthesis of 1,25-dihydroxy
vitamin D [1,25(OH)2D] in the renal proximal tubules. Both
of these effects serve to lower serum phosphate levels.9,10.
Battery of tests recruited for diagnosing TIO should include
serum measurements for phosphate, calcium, alkaline phos-
phatase, creatinine, PTH and 1,25(OH)D and a fasting 2-h ur-
ine for the measurement of phosphate, creatinine, calcium,
amino acids and glucose. In addition, the tubular reabsorption
of phosphate (TmP/GFR) should be calculated: 1 – urine
phosphorous · serum creatinine/urine creatinine · serum
phosphorus (milligrams per deciliter), as was done in our case.
Assays for FGF23 have become available which has
increased chances of diagnosing FGF23-related hypophospha-
temia drastically.11
As TIO can be totally cured by complete surgical resection,
localising the tumour is critical. These tumours are often found
in the unexpected anatomical regions. Thus, a careful physical
examination should be focused in these areas. Imaging tech-
niques like MRI, CT or PET scans can be used to image areas
of clinical suspicion.12,13
This patient’s tumour originated in the temporal bone, with
erosion of the jugular foramen, which is commonly seen with a
glomus jugulare tumour. Glomus tumours are the most com-
monly diagnosed tumours of this region14 Differential diagno-
sis includes meningioma, neural lesion, carcinoma, and
occasionally cholesteatoma. Patients with glomus jugulare
tumours present with pulsatile tinnitus and hearing loss, as
their main complaints were consistent with the patient’s clini-
cal history. However Glomus jugulare tumours, histologically,
have characteristic clusters (zellballen) of epitheliod chief cellsand sustentacular cells with multiple small blood vessels which
were inconsistent with our histopathological study.15
TIO-associated mesenchymal tumours are generally consid-
ered a heterogeneous population; however, roughly 90% rep-
resent phosphaturic mesenchymal tumours of mixed
connective tissue type as per recent studies.16–18
Surgical treatment with en bloc excision of the primary le-
sion is by far the treatment of choice. Medical treatment of
TIO is mainly symptomatic and includes phosphate supple-
ments and calcitriol.19The most common side effect of phos-
phate supplementation is diarrhoea. Patients should be
carefully monitored for hypercalciuria and nephrocalcinosis.
Cinacalet (a calcium-sensing receptor agonist) can be used as
an adjunct to induce hypoparathyroidism. This helps due to
the fact that full phosphaturic effect of FGF23 is dependent
on PTH.20
The tumour may arise from any mesenchymal tissue,
including bone and soft tissue. In head and neck, only few doc-
umented cases have been found in sinonasal area, mandible,
nasopharynx, skull base, and gingiva.21
Tumour origin in the temporal bone, as in the present case,
appears to be extremely rare; to our knowledge the literature
contains only two other similar cases.22,23.However this seems
to be the ﬁrst such case report from India.
4. Conclusion
In conclusion, we investigated and managed a 49-year-old man
with TIO in whom the primary lesion was in the left temporal
bone. Although this is a rare site for the primary lesion, clinical
features and pathologic ﬁndings were typical. Along with spe-
ciﬁc laboratory tests, serum level of FGF-23 aided the diagnos-
tic process and also helped in periodic assessment of the
patient.
Other possible causes of renal phosphate wasting with
elevated FGF23 were ruled out due to the fact that our patient
was well until the age of 49 years with no family history of
bone disease or hypophosphatemia. Moresoever biopsy
proved the pathology in the left temporal bone to be FGF
23 secreting mesenchymal tumour which was removed by
lateral skull approach in toto. After complete resection, all
symptoms were resolved and he has remained free of recur-
rence for 8 months. Our patient’s clinical course highlights
both the difﬁculty in diagnosing TIO and the rapid clinical
improvement when the tumour is removed.
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